Evidence map›Paper›PMID 41964704›Full record

ArticleJournal of neurology2026

Safety and efficacy of anticoagulation for cerebral amyloid angiopathy patients with high-risk atrial fibrillation.

Huanwen Chen, Jay Kakadiya, Hamza A Salim, Muhammed Amir Essibayi, Amelia Adcock, Vivek S Yedavalli, Adam A Dmytriw, Marco Colasurdo, Ajay Malhotra, Dheeraj Gandhi and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Huanwen ChenDepartment of Neurology, University of Maryland Medical Center, Baltimore, MD, 21201, USA.
Jay KakadiyaDivision of Neuroradiology, Department of Radiology and Radiological Sciences, Johns Hopkins University, Baltimore, MD, USA.ORCID http://orcid.org/0009-0009-2075-6562
Hamza A SalimDepartment of Neuroradiology, MD Anderson Cancer Center, Houston, TX, USA.
Muhammed Amir EssibayiDepartment of Neurological Surgery, Montefiore Medical Center, The University Hospital for Albert Einstein College of Medicine, Bronx, NY, USA.
Amelia AdcockDepartment of Neurology, Rockefeller Neuroscience Institute, West Virginia University, Morgantown, WV, 26505, USA.
Vivek S YedavalliDivision of Neuroradiology, Department of Radiology and Radiological Sciences, Johns Hopkins University, Baltimore, MD, USA.
Adam A DmytriwNeuroendovascular Program, Massachusetts General Hospital & Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Marco ColasurdoDepartment of Interventional Radiology, Oregon Health and Science University, Portland, OR, USA.
Ajay MalhotraDepartment of Radiology, Yale New Haven Hospital, New Haven, CT, USA.
Dheeraj GandhiDepartment of Neurosurgery, University of Maryland Medical Center, Baltimore, MD, USA.
Dhairya A LakhaniDepartment of Neurology, Rockefeller Neuroscience Institute, West Virginia University, Morgantown, WV, 26505, USA. dhairyalakhani@gmail.com.ORCID http://orcid.org/0000-0001-7577-1887

Funding

NIGMS NIH HHS 5U54GM104942-08
6 · The paper itself

Abstract

backgroundCerebral amyloid angiopathy (CAA) significantly increases intracranial hemorrhage (ICH) risk and the safety of anticoagulation (AC) among CAA patients with atrial fibrillation (AF) is uncertain.

methodsThis was a retrospective cohort study of the TriNetX US collaborative network. Elderly CAA patients (≥ 65 years old) with newly diagnosed high-risk AF (CHA₂DS₂-VASc ≥ 2 for men and ≥ 3 for women) were included; patients with prior ischemic or hemorrhagic stroke were excluded. Patients treated with apixaban or rivaroxaban were compared to no AC treatment. Propensity score matching (PSM) was used to balance groups. Primary outcomes were ischemic stroke and ICH within 3 years assessed with Kaplan-Meier analyses; secondary outcomes included major hemorrhage and patient death.

results821 patients were included (462 AC, 359 no AC); after PSM, 287 patients remained in each group. AC was significantly associated with lower stroke risk (event probability 1.0% vs 5.7% at 3 years, p = 0.016) without increasing intracerebral hemorrhage risk (3.0% vs 3.9%, p = 0.21). Major hemorrhage rates were comparable (8.1% vs 10.7%, p = 0.09), and mortality was lower with AC (27.9% vs 33.5%, p = 0.049).

conclusionsAnticoagulation for elderly CAA patients with newly diagnosed high-risk AF and without prior history of ischemic or hemorrhagic stroke was associated with lower risks of ischemic stroke and death without higher risk of hemorrhage.

Indexed as

AnticoagulantsAtrial FibrillationCerebral Amyloid AngiopathyIschemic StrokeAgedAged, 80 and overFemaleHumansMaleRetrospective StudiesAnticoagulantsAtrial fibrillationCerebral amyloid angiopathyIntracranial hemorrhageReadmissionsStrokeTriNetX

Identifiers

PMID41964704

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.